A precision medicine model for targeted NSAID therapy in Alzheimer’s disease

Manuscript Number: 

18-0619R1

Author(s): 
Melissa Edwards, Paula Grammas, James Hall, Leigh A. Johnson, Constantine G. Lyketsos, Esther S. Oh, Sid E. O’Bryant, Robert A. Rissman, Fan Zhang

Disclosures

Melissa Edwards

  • Nothing to Disclose

Paula Grammas

  • Nothing to Disclose

James Hall

  • Nothing to Disclose

Leigh A. Johnson

  • Equity:
    Dr. Leigh Johnson has a financial interest in CX Precision Medicine. CX Precision Medicine had no role in the design or results of this study.

Constantine G. Lyketsos

  • Consulting Fees:
    Since 1993: Grant support (research or CME): NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan, Functional Neuromodulation Consultant/Advisor: Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Abvie, Janssen, Orion, Otsuka, Astellas, Merck Honorarium or travel support: Pfizer, Forest, Glaxo-Smith Kline, Health Monitor
    Grants
    • Agency: 
      Functional Neuromodulation Ltd
      Dates: 
      2014-active

Esther S. Oh

  • Nothing to Disclose

Sid E. O’Bryant

  • Equity:
    Dr. O'Bryant is founding scientist and owns stock options in Cx Precision Medicine, Inc.
    Patents/Royalties
    Dr. O'Bryant has multiple pending patents on precision medicine for Alzheimer's disease and other neurodegenerative diseases.

Robert A. Rissman

  • Nothing to Disclose

Fan Zhang

  • Nothing to Disclose